Verlyx Pharma Inc. is a privately-held pharmaceutical company involved in the development of liver-targeting therapeutic agents for the treatment of liver diseases. Verlyx’s lead product, VLX103, is a proprietary form of pentamidine that combines hepatoselective and hepatoprotective properties. Verlyx has initiated a purposeful clinical program based on VLX103, aiming at three important unmet needs in the field of liver diseases: NASH and ASH.
Verlyx Pharma relies on accomplished individuals whose complementary expertise brings a high level of knowledge, innovation and management to the company. This team coordinates a network of collaborators and investigators dedicated to the success of the company and its products.
Company Details
- Founded
- 2000
- Address
- 555 Boul Rene Levesque West, 9th Floor,canada
- in****@****lyx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- verlyx.com
- Keywords
- Kennesaw.
- HQ
- Montreal, Quebec
Verlyx Pharma Questions
Verlyx Pharma's website is verlyx.com
Verlyx Pharma's LinkedIn profile is https://ca.linkedin.com/company/verlyx-pharma
Verlyx Pharma's industry is
Biotechnology Research
Verlyx Pharma's top competitors are
Premier Research,
Inversago Pharma,
Biotecanada,
Scienceindustries,
Guardian Pharmacy,
Innospera Pharma,
Iou Financial,
Theratechnologies Inc.,
Lonza,
Bdc.
Verlyx Pharma's support email address is info@verlyx.com
Verlyx Pharma's categories are Biotechnology Research
Verlyx Pharma's founding year is 2000
